Biopharma · FDA Approvals · Stock

PTN Palatin Technologies

Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial po…

Assets on file: PL2000, PL2001

Catalyst calendar

Dated catalysts for PTN, including recently decided ones.

Recent first-hand events

Every first-hand event for PTN, newest first.

Instant stream — events appear as soon as they are filed.
Decision-gradeMaterialNotableMinor
Nov 17, 2026
12:30 PM
PTNPalatin Technologies, Inc.

Palatin Advances PL2000 MC4R Agonist to Phase 1 in H1 2027

Palatin is advancing its lead lipidated PL2000 MC4R-selective peptide through ongoing IND-enabling studies and CMC activities. The company targets initiation of a Phase 1 SAD/MAD study in the first half of calendar 2027, with initial data expected in the second half of 2027. Preclinical data support once-weekly dosing and minimal MC1R activity to reduce hyperpigmentation risk.

Nov 14, 2026
12:00 PM
PTNPalatin Technologies, Inc.

Palatin Presents Preclinical Data on MC4R Agonist PL2001 at ObesityWeek 2026

Palatin presented new preclinical data at ObesityWeek 2026 showing its novel MC4R-selective peptide agonists (including lead PL2001) have potent MC4R activity with >100-fold selectivity over MC1R, significant body weight and food intake reductions in DIO mice, extended half-life supporting once-weekly dosing via lipidation, and no cardiovascular effects at efficacious doses. PL2001 was selected as development candidate with first-in-human studies targeted for H1 2027.

Conference presentationCompany press release

Peers by market cap

Companies in the same sector closest to PTN in market value.

PTN FDA Calendar & Catalysts — Palatin Technologies | Biopharma · FDA Approvals | SimianX AI